| (P313) |
Positive feedback mechanism between extracellular matrix metalloproteinase inducer (EMMPRIN) and metalloproteinases – implication in the development of plaque instability. |
|
M. Bachem, V. Kreutle, F. Diaz, S. Zhou, Chr. Lenz, Ph. Lepper, X. Zhang, C. Haug (Ulm, DE) |
| (P314) |
The polymorphism C1562-T in the matrix Metalloproteinase-9 promoter and susceptibility to sporadic abdominal aortic aneurysm. |
|
C. Armani, M. Nuti, M.C. Barsotti, T. Santoni, F. Massart, R. Di Stefano, M. Dell'Omodarme, M.C. Prati, M. Ferrari, A. Balbarini (Pisa, IT) |
| (P315) |
The activated complement component C5a up-regulates the matrix metalloproteinases MMP-1 and MMP-9 in human monocyte derived macrophages. |
|
W. Speidl, S.P. Kastl, Chr. Kaun, Ph.J. Hohensinner, G. Maurer, K. Huber, J. Wojta (Vienna, AT) |
| (P316) |
Small interfering RNA for in vitro and ex vivo MMP2 gene regulation in vascular smooth muscle cells. |
|
H. Hlawaty, A. San Juan, M-P. Jacob, R. Vranckx, D. Letourneur, L. Feldman, on behalf of Hemostase, Bioingenierie et Remodelages Vasculaires (Paris, FR) |
| (P317) |
Regulation of tissue inhibitor of metalloproteinases (TIMP)-1 expression by parathyroid hormone-related protein (PTHrP) in microvascular endothelial cells. |
|
C. Conzelmann, K. Weber, K-D. Schlüter (Gießen, DE) |
| (P318) |
Ionizing radiation accelerates the development of atherosclerotic lesions and results in intraplaque hemorrhage in ApoE-/- mice. |
|
S. Heeneman, M. Gijbels, H. te Poele, J. Kruse, N. Russell, M. Daemen, F. Stewart (Maastricht and Amsterdam, NL) |
| (P319) |
Adenoviral mediated overexpression of VEGF leads to a vulnerable plaque phenotype in ApoE-deficient mice. |
|
M. Lucerna, R. de Nooijer, A. Zernecke, I. Bot, S. de Jager, T. van Berkel, Chr. Weber, E. Biessen (Leiden, NL; Aachen, DE) |
| (P320) |
Thrombin inhibition with melagatran suppresses atherosclerotic plaque development in apolipoprotein E knockout mice. |
|
S. Karanam, R. Fritsche-Danielson, Chr. Jackson (Bristol, GB; Mölndal, SE) |
| (P321) |
Plaque charactaristics are related to symptomatic carotid patients. |
|
W.E. Hellings, B.A.N. Verhoeven, F.L. Moll, C.A. Seldenrijk, D.P.V. de Kleijn, E. Velema, J-P.P.M. de Vries, G. Pasterkamp (Utrecht and Nieuwegein, NL) |
| (P322) |
ED-A, an endogenous ligand for toll like receptor -4, is not associated with the extent or progression of atherosclerotic disease or atherosclerotic plaque phenotype. |
|
K. van Keulen, A. Schoneveld, F. Moll, Y. de Graaf, D. de Kleijn, G. Pasterkamp (Utrecht, NL) |
| (P323) |
HIF 1α, 2α and target gene expression in vulnerable human atherosclerotic plaques. |
|
J.C. Sluimer, J.M. Gasc, D. Black, P. Aarts, L.H. Van den Akker, P. Corvol, M.J. Daemen, A.P. Bijnens (Maastricht and Sittard, NL; Paris, FR; Newhouse, GB) |
| (P324) |
A destabilising role for cathepsin S in murine and human atherosclerotic plaques. |
|
K. Rodgers, D. Watkins, A. Miller, P. Chan, W. Brissette, C. Long, Chr. Jackson (Bristol and Sandwich, GB; Sydney, AU; Groton, US) |
| (P325) |
Statin use and plaque phenotype: a retrospective study in 378 patients undergoing carotid endarterectomy. |
|
W.E. Hellings, B.A.N. Verhoeven, F.L. Moll, J. Koekkoek, J-P.P.M. de Vries, E. Velema, P. de Bruin, G. Pasterkamp (Utrecht and Nieuwegein, NL) |